We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRegulus Therapeutics Inc

Regulus Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-07-24T13:11:23.467413Z
Market Cap
133.88M

Momentum Score

…

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.08
Low
3.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
5.00M
Revenue Per Share
0.07
Gross Profit TTM
-18.41M
Debt / Equity
0.15
ROE
-110.27%
Net Debt
-20.73M
ROCE
-127.51%
Diluted EPS TTM
-1.47

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -28.32M -27.81M -15.73M -18.59M -48.65M
Net income -28.32M -27.81M -15.26M -18.59M -48.71M
Selling general administrative 9.83M 10.02M 8.81M 11.32M 12.86M
Gross profit - - 10.01M 6.83M 0.07M
Reconciled depreciation 0.12M 0.46M 0.47M 0.93M 2.26M
Ebit -28.36M -28.27M -14.62M -17.77M -49.02M
Ebitda -28.24M -27.82M -14.15M -16.83M -46.76M
Depreciation and amortization 0.12M 0.46M 0.47M 0.93M 2.26M
Non operating income net other - - 0.23M 0.37M 0.46M
Operating income -28.24M -27.82M -14.15M -16.83M -46.76M
Other operating expenses 28.24M 27.82M 24.16M 23.67M 46.84M
Interest expense 0.69M 0.85M 1.81M 2.13M 2.34M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.06M
Interest income 0.60M 0.86M 0.23M 0.37M 0.46M
Net interest income -0.08M 0.01M -1.57M -1.76M -1.88M
Income tax expense 0.00M 0.00M -0.47M 0.00M 0.06M
Total revenue 0.00M 0.01M 10.01M 6.83M 0.07M
Total operating expenses 28.24M 27.82M 24.16M 23.67M 46.84M
Cost of revenue - - - 12.35M 33.98M
Total other income expense net -0.08M 0.01M -1.57M -1.76M -1.88M
Net income from continuing ops -28.32M -27.81M -15.73M -18.59M -48.71M
Net income applicable to common shares -28.32M -27.81M -15.73M -18.59M -48.71M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 30.75M 46.72M 68.45M 37.60M 42.08M
Intangible assets 0.03M 0.06M 0.08M 0.12M 0.27M
Other current assets 1.34M 1.85M 1.78M 1.83M 1.22M
Total liab 9.56M 13.43M 13.50M 11.58M 22.07M
Total stockholder equity 21.19M 33.29M 54.96M 26.03M 20.02M
Other current liab 6.26M 6.97M 4.94M 2.97M 5.64M
Common stock 0.02M 0.02M 0.15M 0.07M 0.02M
Capital stock 0.03M 0.02M 0.15M 0.07M 0.03M
Retained earnings -513.21M -483.18M -454.85M -427.05M -411.31M
Other liab - - 1.18M - 0.47M
Other assets 0.00M - 0.29M 0.02M 0.02M
Cash 23.83M 24.23M 60.38M 31.09M 34.12M
Total current liabilities 8.51M 11.66M 5.23M 11.58M 21.60M
Current deferred revenue - - - 3.42M 0.01M
Net debt -20.73M -17.95M -53.29M -26.43M -19.49M
Short term debt 2.05M 4.51M 4.67M 4.65M 14.63M
Short long term debt 1.33M 4.51M - 4.65M 14.63M
Short long term debt total 3.10M 6.28M 7.09M 4.65M 14.63M
Other stockholder equity 534.38M 516.46M 509.66M 453.00M 431.31M
Property plant equipment - 2.58M 2.85M 0.72M 0.92M
Total current assets 25.17M 44.08M 65.23M 36.73M 40.41M
Net tangible assets - 33.22M 28.92M 25.90M 19.75M
Short term investments 0.00M 14.93M - - -
Net receivables -0.00M - 0.00M 0.50M 1.14M
Long term debt - - 4.67M - -
Inventory 0.00M 3.01M 3.01M 3.31M 3.92M
Accounts payable 0.20M 0.17M 0.28M 0.54M 1.32M
Accumulated other comprehensive income -0.00M -0.01M - - -4.41M
Common stock total equity - - - 0.07M 0.02M
Preferred stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -427.05M -411.31M
Non currrent assets other 3.01M - 0.29M 0.28M 0.49M
Non current assets total 5.58M 2.64M 3.22M 0.87M 1.67M
Capital lease obligations 1.05M 1.77M 2.42M - -
Long term debt total - - - - 0.06M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -15.12M -0.25M -0.01M 0.07M 46.54M
Change to liabilities -0.11M -0.25M -1.84M -2.92M -5.78M
Total cashflows from investing activities -15.12M -0.25M -0.01M 0.07M 46.52M
Net borrowings - -0.08M -10.00M -1.98M -3.34M
Total cash from financing activities 4.49M 53.74M 9.51M 39.93M -2.83M
Change to operating activities 0.66M 0.36M -0.50M -2.77M -2.05M
Net income -28.32M -27.81M -15.73M -18.59M -48.71M
Change in cash -36.16M 29.36M -3.03M 20.19M 0.42M
Begin period cash flow 60.45M 31.09M 34.12M 13.94M 13.52M
End period cash flow 24.29M 60.45M 31.09M 34.12M 13.94M
Total cash from operating activities -25.53M -24.13M -12.54M -19.82M -43.27M
Issuance of capital stock 4.49M 53.79M 19.12M 42.17M 0.22M
Depreciation 0.12M 0.46M 0.47M 0.93M 2.26M
Other cashflows from investing activities - - -0.01M 0.29M 46.54M
Change to inventory - 0.30M 0.61M 0.27M -0.61M
Change to account receivables - 0.50M 0.64M -1.11M 0.35M
Sale purchase of stock - - 19.13M 42.17M 0.22M
Other cashflows from financing activities -15.12M 0.03M 0.67M 0.00M 0.29M
Change to netincome 2.12M 2.31M 2.77M 2.58M 6.20M
Capital expenditures 0.36M 0.25M 0.01M 0.24M 0.02M
Change receivables - - 0.64M -1.11M 0.35M
Cash flows other operating - - 1.16M -0.70M 2.27M
Cash and cash equivalents changes - - -3.03M 20.19M 0.42M
Change in working capital 0.55M 0.91M -0.04M -6.58M -3.17M
Stock based compensation 2.18M 2.92M 2.61M 2.29M 5.44M
Other non cash items -0.05M 0.05M 0.15M 2.13M 0.76M
Free cash flow -25.89M -24.38M -12.55M -20.07M -43.30M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

4224 Campus Point Court, San Diego, CA, United States, 92121

858 202 6300

https://www.regulusrx.com

30

Name Title Year Born
Mr. Joseph P. Hagan M.B.A. Pres, CEO & Director 1969
Ms. Crispina Calsada CPA Chief Financial Officer 1970
Mr. Christopher Ray Aker J.D. Sr. VP, Gen. Counsel & Corp. Sec. 1961
Mr. Daniel J. Penksa Sr. Director of Fin. & Controller 1986
Mr. Firuz Shakoori Head of CMC NA
Dr. Claire Susan Padgett M.S., M.T., Ph.D. Sr. VP of Clinical Operations NA
Dr. Rekha Garg M.D., M.S. Sr. VP of Clinical Devel. & Regulatory NA
Mr. Joseph P. Hagan M.B.A. CEO & Director 1969
Mr. Christopher Ray Aker J.D. Senior VP, General Counsel & Corporate Secretary 1961
Dr. Preston S. Klassen M.D., M.H.S. President, Head of Research & Development and Director 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…